Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers

Abstract With disease-modifying treatment for Parkinson’s disease (PD) associated with variants in the glucocerebrosidase gene (GBA1) under way, the challenge to design clinical trials with non-PD-manifest GBA mutation carriers (GBA1NMC) comes within close reach. To delineate trajectories of motor a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Benjamin Roeben, Inga Liepelt-Scarfone, Stefanie Lerche, Milan Zimmermann, Isabel Wurster, Ulrike Sünkel, Claudia Schulte, Christian Deuschle, Gerhard W. Eschweiler, Walter Maetzler, Thomas Gasser, Daniela Berg, Kathrin Brockmann
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-04-01
Col·lecció:	npj Parkinson's Disease
Accés en línia:	https://doi.org/10.1038/s41531-024-00706-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!